Clinical Trials Logo

T-Cell Lymphoma Relapsed clinical trials

View clinical trials related to T-Cell Lymphoma Relapsed.

Filter by:
  • None
  • Page 1

NCT ID: NCT03552692 Terminated - Clinical trials for T-Cell Lymphoma Relapsed

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Start date: September 25, 2018
Phase: Phase 2
Study type: Interventional

The FIL_VERT study is a phase II, open label, multicenter clinical trial. The primary of objective of the Study is to evaluate the efficacy of Venetoclax ABT-199/GDC-0199) in terms of overall response rate (ORR) in patients with relapsed/refractory BCL-2 positive peripheral T cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal T-cell lymphomas of T-follicular helper origin (TFH)

NCT ID: NCT03046953 Completed - Clinical trials for T-Cell Lymphoma Relapsed

Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma

AVAIL-T
Start date: November 14, 2017
Phase: Phase 2
Study type: Interventional

The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refratory to or has relapsed following initial treatment.

NCT ID: NCT02689453 Completed - Clinical trials for T-Cell Prolymphocytic Leukemia

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

Start date: January 19, 2017
Phase: Phase 1
Study type: Interventional

Background: Adult T-cell leukemia (ATL) is a rare blood cancer. Researchers want to see if a combination of two drugs - recombinant human interleukin 15 (rhIL-15) and alemtuzumab - is a better treatment for ATL. Objectives: To test if giving rhIL-15 combined with alemtuzumab improves the outcome of therapy for ATL. Also, to determine the safe dose of this combination and identify side effects and effects on the immune system. Eligibility: Adults 18 years and older with chronic or acute ATL who have not been helped by other treatments. Design: Participants will be screened with tests that are mostly part of their usual cancer care. They will sign a separate consent form for this. Weeks 1 and 2: Participants will have a total of 10 visits. They will: - Get rhIL-15 under the skin by needle. - Have a physical exam and vital signs measured. - Give blood samples. - Answer questions about their health and their medicines. Week 3: Participants will stay in the clinic. They will: - Get alemtuzumab infusions in a vein through a small catheter on days 1, 2, 3, and 5. - Take medicines to decrease side effects. - Have a computed tomography (CT) scan to evaluate the treatment. - Have a physical exam and vital signs measured. - Give blood samples. Answer questions about their health and medicines. Weeks 4, 5, and 6 will repeat week 3, without the CT scan. Some patients will just have outpatient visits these weeks. After treatment, participants will have follow-up visits every few months for up to 2 years. At these visits, participants will give blood samples and have CT scans.